Cellceutix Completes Patient Enrollment of Final Cohort in Phase 2 Trial of Brilacidin for Inflammatory Bowel Disease; Topline Results Anticipated in July
May 18, 2017 09:30 ET
|
Cellceutix Corporation
BEVERLY, Mass., May 18, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), is pleased to announce that patient enrollment has been completed in the third and final cohort...
Cellceutix Provides Corporate Update; Significant Milestones Ahead as Multiple Mid-Phase Clinical Trials Set to Conclude
May 10, 2017 09:45 ET
|
Cellceutix Corporation
BEVERLY, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Announces Details for Upcoming Investor and Shareholder Presentations
April 19, 2017 16:15 ET
|
Cellceutix Corporation
BEVERLY, Mass., April 19, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCQB:CTIX), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology,...
Cellceutix CEO Discusses Brilacidin Following Interim Trial Results for Treating Oral Mucositis and Inflammatory Bowel Disease
April 10, 2017 07:30 ET
|
Cellceutix Corporation
BEVERLY, Mass., April 10, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation (OTCQB:CTIX), Accelerating Phase 2 trial for the Prevention of Severe Oral Mucositis (SOM)Annual Global Market for SOM may...
Cellceutix AACR Poster Presents Data Supporting Kevetrin Modulation of p53 in Multiple Human Ovarian Cancer Cell-lines and Corresponding Xenograft Tumors
April 03, 2017 07:30 ET
|
Cellceutix Corporation
BEVERLY, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), is pleased to share further data supporting the p53 mechanism of action of Kevetrin in...
Cellceutix Reports Very Encouraging Interim Analysis of Phase 2 Drug Candidate Brilacidin for Severe Oral Mucositis (OM) in Head and Neck Cancer Patients; High Potential for Preventative Treatment
March 27, 2017 10:00 ET
|
Cellceutix Corporation
BEVERLY, Mass., March 27, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), today presented positive results from the Company's ongoing randomized, double-blind Phase 2...
Cellceutix Releases Favorable Topline Findings as Part of Interim Analysis of Phase 2 Drug Candidate Brilacidin for the Treatment of Inflammatory Bowel Disease
March 21, 2017 07:30 ET
|
Cellceutix Corporation
BEVERLY, Mass., March 21, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix’s Phase 2 Drug Candidate Brilacidin Emerging as a Potential Novel Non-Biologic Therapy in Treating Inflammatory Bowel Disease
March 16, 2017 07:30 ET
|
Cellceutix Corporation
BEVERLY, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Releases Preliminary Efficacy and Safety Data in Interim Analysis of First Two Cohorts in Phase 2 Trial of Brilacidin for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis
March 08, 2017 07:30 ET
|
Cellceutix Corporation
BEVERLY, Mass., March 08, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...
Cellceutix Provides Update on Developing p53 Drug Candidate Kevetrin as an Oral Anti-Cancer Agent
March 03, 2017 15:50 ET
|
Cellceutix Corporation
BEVERLY, Mass., March 03, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology,...